Literature DB >> 26149534

Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure.

Troy C Lund1, Jessica Liegel2, Nelli Bejanyan2, Paul J Orchard1, Qing Cao3, Jakub Tolar1, Claudio Brunstein2, John E Wagner1, Michael R Verneris1, Daniel Weisdorf2.   

Abstract

Graft failure (GF) after hematopoietic cell transplant (HCT) occurs in 5-30% of patients. GF can be accompanied by neutropenia (NGF) or can result with adequate neutrophils, but loss of donor chimerism (non-neutropenic graft failure, NNGF). In this report, we describe the outcomes of 95 patients treated with a second HCT for GF at the University of Minnesota; 62 with NGF and 33 with NNGF. The cumulative incidence of neutrophil recovery at 42 days after second HCT was 45% for NGF and 88% for NNGF. A second GF occurred in 34 NGF (55%) and in 9 NNGF (27%) patients. The incidence of Grade III-IV acute graft versus host disease (GVHD) was 8% (95% confidence interval (CI), 1-16%) and 12% (95% CI, 1-23%) for NGF and NNGF, respectively. From the 2nd HCT, 1-year overall survival (OS) was 44% (95% CI, 34-54%), [NNGF: 76% (95% CI, 57-87%) and NGF: 27% (95% CI, 17-39%)]. The most common cause of death after second HCT was infection (52%). In summary, the outcomes of second HCT after NGF and NNGF are different with much worse outcomes for NGF necessitating new approaches for this complication.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26149534      PMCID: PMC4579006          DOI: 10.1002/ajh.24111

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  30 in total

Review 1.  Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation.

Authors:  S N Wolff
Journal:  Bone Marrow Transplant       Date:  2002-04       Impact factor: 5.483

2.  T cell-depleted related HLA-mismatched peripheral blood stem cell transplantation as salvage therapy for graft failure after single unit unrelated donor umbilical cord blood transplantation.

Authors:  Federico Moscardó; Samuel Romero; Jaime Sanz; Miguel A Sanz; Pau Montesinos; Ignacio Lorenzo; Pilar Solves; Nelly Carpio; Guillermo F Sanz
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-28       Impact factor: 5.742

3.  Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study.

Authors:  Rémy Dulery; Julia Salleron; Anny Dewilde; Julien Rossignol; Eileen M Boyle; Julie Gay; Eva de Berranger; Valerie Coiteux; Jean-Pierre Jouet; Alain Duhamel; Ibrahim Yakoub-Agha
Journal:  Biol Blood Marrow Transplant       Date:  2011-12-30       Impact factor: 5.742

4.  Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: a retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplantation.

Authors:  Shigeo Fuji; Fumiaki Nakamura; Kazuo Hatanaka; Shuichi Taniguchi; Maho Sato; Shin-Ichiro Mori; Hisashi Sakamaki; Hiromasa Yabe; Toshihiro Miyamoto; Heiwa Kanamori; Yasunori Ueda; Keisei Kawa; Koji Kato; Ritsuro Suzuki; Yoshiko Atsuta; Toshiharu Tamaki; Yoshinobu Kanda
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-16       Impact factor: 5.742

5.  Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program.

Authors:  S M Davies; C Kollman; C Anasetti; J H Antin; J Gajewski; J T Casper; A Nademanee; H Noreen; R King; D Confer; N A Kernan
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

6.  Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de moelle (SFGM).

Authors:  M Michallet; M L Tanguy; G Socié; A Thiébaut; A Belhabri; N Milpied; J Reiffers; M Kuentz; J Y Cahn; D Blaise; F Demeocq; J P Jouet; A S Michallet; N Ifrah; E Vilmer; L Molina; G Michel; B Lioure; M Cavazzana-Calvo; J L Pico; A Sadoun; D Guyotat; M Attal; H Curé; P Bordigoni; L Sutton; A Buzyn-Veil; M Tilly; N Keoirruer; N Feguex
Journal:  Br J Haematol       Date:  2000-02       Impact factor: 6.998

7.  Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients.

Authors:  Prakash Satwani; Zhezhen Jin; Deirdre Duffy; Erin Morris; Monica Bhatia; James H Garvin; Diane George; Mary Brigid Bradley; Lauren Harrison; Kristen Petrillo; Joseph Schwartz; Sandra Foley; Ria Hawks; Lee Ann Baxter-Lowe; Mitchell S Cairo
Journal:  Biol Blood Marrow Transplant       Date:  2012-12-16       Impact factor: 5.742

8.  Graft failure in the modern era of allogeneic hematopoietic SCT.

Authors:  R Olsson; M Remberger; M Schaffer; D M Berggren; B-M Svahn; J Mattsson; O Ringden
Journal:  Bone Marrow Transplant       Date:  2012-12-10       Impact factor: 5.483

9.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival.

Authors:  John E Wagner; Juliet N Barker; Todd E DeFor; K Scott Baker; Bruce R Blazar; Cindy Eide; Anne Goldman; John Kersey; William Krivit; Margaret L MacMillan; Paul J Orchard; Charles Peters; Daniel J Weisdorf; Norma K C Ramsay; Stella M Davies
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

10.  Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia.

Authors:  R Storb; R L Prentice; E D Thomas; F R Appelbaum; H J Deeg; K Doney; A Fefer; B W Goodell; E Mickelson; P Stewart
Journal:  Br J Haematol       Date:  1983-12       Impact factor: 6.998

View more
  6 in total

1.  Non-myeloablative conditioning for second hematopoietic cell transplantation for graft failure in patients with non-malignant disorders: a prospective study and review of the literature.

Authors:  K Mallhi; P J Orchard; W P Miller; Q Cao; J Tolar; T C Lund
Journal:  Bone Marrow Transplant       Date:  2017-01-16       Impact factor: 5.483

Review 2.  Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review.

Authors:  Ashvind Prabahran; Rachel Koldej; Lynette Chee; Jeff Szer; David Ritchie
Journal:  Bone Marrow Transplant       Date:  2022-07-23       Impact factor: 5.174

3.  Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation.

Authors:  Kaito Harada; Shigeo Fuji; Sachiko Seo; Junya Kanda; Toshimitsu Ueki; Fumihiko Kimura; Koji Kato; Naoyuki Uchida; Kazuhiro Ikegame; Makoto Onizuka; Ken-Ichi Matsuoka; Noriko Doki; Toshiro Kawakita; Yasushi Onishi; Shingo Yano; Takahiro Fukuda; Minoko Takanashi; Yoshinobu Kanda; Yoshiko Atsuta; Masao Ogata
Journal:  Bone Marrow Transplant       Date:  2020-02-12       Impact factor: 5.483

4.  [Risk-factors analysis of graft failure after allogeneic hematopoietic stem cell transplantation].

Authors:  Y Fei; X X Hu; Q Chen; A J Huang; H Cheng; X Ni; L Chen; L Gao; G S Tang; J Chen; W P Zhang; J M Yang; J M Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

Review 5.  Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation.

Authors:  Juan Chen; Hongtao Wang; Jiaxi Zhou; Sizhou Feng
Journal:  Ther Adv Hematol       Date:  2020-08-17

6.  Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party.

Authors:  Patrick J Hayden; Dirk-Jan Eikema; Liesbeth C de Wreede; Linda Koster; Nicolaus Kröger; Hermann Einsele; Monique Minnema; Alida Dominietto; Michael Potter; Jacob Passweg; Arancha Bermúdez; Stephanie Nguyen-Quoc; Uwe Platzbecker; Johanna Tischer; Fabio Ciceri; Joan Hendrik Veelken; Per Ljungman; Nicolaas Schaap; Edouard Forcade; Angelo Michele Carella; Virginie Gandemer; William Arcese; Adrian Bloor; Attilio Olivieri; Laure Vincent; Meral Beksac; Stefan Schönland; Ibrahim Yakoub-Agha
Journal:  Bone Marrow Transplant       Date:  2021-05-11       Impact factor: 5.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.